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ABSTRACT 
Objective: The objective of the present study was to develop “once daily” extended-release tablets of tramadol (100 mg) by wet granulation using 
hydrophilic polymer like hydroxypropyl methylcellulose K100M, K15M and polyethylene oxide (PEO). 
Methods: The tramadol matrix tablets were prepared by using different polymers like hydroxypropyl methyl cellulose (HPMC K15M and K100M), 
polyethylene oxide (PEO) as the nontoxic and easily available suitable matrix system. The extended-release tablets of tramadol (400 mg) were 
prepared wet granulation technique. Different pre-compression and post-compression were performed. In vitro dissolution tests were performed 
and percentage drug release was calculated. The Fourier-transform infrared spectroscopy (FTIR) studies conducted on pure drug tramadol and the 
optimized formulation (T6). Different release models like zero order, first order, higuchi and Korsemeyer-Peppas were applied to in vitro drug 
release data in order to evaluate the drug release mechanisms and kinetics.  
Results: Pre-compression and post-compression parameters satisfied with pharmacopeia specifications. The In vitro release studies were 
performed using USP type II apparatus showed that optimized formulation T6 consisting of polyethylene oxide (PEO) with 25 mg of the polymer 
was found to extended release of tramadol over a period of 24h. The optimized formulation T6 followed the zero-order kinetics as correlation 
coefficient (r2
Conclusion: The present study shows that polyethylene oxide was found to play a great role in controlling release of tramadol from the matrix 
system. Accordingly, it can be concluded that the formulation is robust in the performance is less likely to be affected by the various factors studied. 
) values are higher than that of first-order release kinetics. In order to understand the complex mechanism of drug release from the 
optimized formulation T6 matrix system, the in vitro release rate were fitted to Korsemeyer-Peppas model and the release exponent value (n) 
obtained was 0.82105 exhibited anomalous (non fickian) diffusion mechanism. 
Keywords: HPMC K100M, Polyethylene oxide, Extended-release (ER), Sustained release (SR) 




Oral drug delivery is the largest and the oldest segment of the total 
drug delivery market. It is the fastest growing and most preferred 
route for drug administration. Increased complications and expense 
involved in the marketing of new drug entities have focused greater 
attention on the development of sustained release (SR) or controlled 
release (CR) or extended release (ER) drug delivery systems [1-3]. 
Sustained release (SR) or controlled release (CR) or extended 
release (ER) delivery systems can achieve predictable and 
reproducible release rates, extended duration of activity for short 
half-life drugs, decreased toxicity, and reduction of required dose, 
optimized therapy and better patient compliance. Sustained release 
(SR) or controlled release (CR) or extended release (ER) drug 
delivery systems are designed by different techniques like enteric 
coating, osmotic pump, prodrugs, transdermal patches and matrix 
tablets. Among the various techniques used, recently the attention of 
pharmaceutical researchers has been attracted by the matrix tablets. 
Matrix type sustained delivery systems are popular because of their 
ease of manufactures. It excludes complex production procedure 
such as coating and pelletization during manufacturing and drug 
release from the dosage form. It is controlled mainly by the type and 
proportion of the polymers used in the preparation. Hydrophilic 
polymer matrix system are widely used for designing oral sustained 
release delivery systems because of their flexibility to provide a 
desirable drug release profile, cost-effectiveness, and broad 
regulatory acceptance [4, 5]. 
Tramadol HCl (TmH) is a centrally acting opioid and nonopioid 
analgesic. TmH acts as an opiate agonist, through selective binding 
to the μ-opioid receptor, and weak inhibition of norepinephrine and 
serotonin uptake. It is used when non-steroidal anti-inflammatory 
drugs (NSAIDs) fail to mitigate pain. It works in the brain to change 
how your body feels and responds to pain. It’s also used to treat 
long-standing pain when weaker painkillers not work.  
The aim of the study was to develop “once daily” extended-release 
tablets of tramadol (100 mg) for the treatment of severe acute and 
chronic pain. Tramadol is readily absorbed after oral administration 
because of tramadol belongs to BCS class I drug has a good 
bioavailability 68-72 % and short half-life (t1/2
MATERIALS AND METHODS 
= 5-6 h). It is 
prescribed 3-4 times a day usual dosage regimen of 50-100 mg and a 
maximum dose 400 mg (50 mg 4 times a day). This frequent dosing 
schedule cause an increased incident of side effects, non-
compliances and development of tolerance especially in long term 
used like osteoarthritis, arthritis, post-surgical pains etc. [6, 7]. It can 
be suggested that there is a strong clinical implication of SR 
formulation of this drug. 
Materials 
Materials used in this study were obtained from different sources. 
Tramadol a gift sample from Chandra lab, hyderabad. Hydroxypropyl 
methylcellulose (HPMC K15M and K100M), polyethylene oxide (PEO), 
magnesium stearate procured from ISP, Hyderabad. Microcrystalline 
cellulose procured from loba chemie pvt ltd, Mumbai. Talc procured 
from SD fine chemicals pvt ltd, Mumbai. 
Methods 
Preformulation studies 
Preformulation is defined as the study of physical and chemical 
properties of a drug substance alone prior to formulation. The overall 
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objective of pre-formulation studies is to generate information useful to 
the formulator in developing stable dosage forms [8]. 
Colour, odour and appearance 
The drug sample was evaluated for its colour and odour. The results 
are shown in table 8. 
Determination of solubility 
The solubility of drug tramadol is determined by using a different 
solvent like water, methanol and acetone. The result are shown in 
table 9. 
Determination of λmax 
Standard stock solution: 100 mg of tramadol was dissolved in a 
sufficient amount of methanol and makeup to 100 ml with 0.1N HCL 
to give a concentration of 1000 μg/ml (stock solution A). 
Scanning: From the stock solution (stock A) pippet out 1 ml and was 
make up to 10 ml to give a concentration 100μg/ml (stock solution 
B) was prepared and UV scan was taken between 200 to 400 nm. 
The absorption maximum was found to be 270 nm and was used for 
further analytical studies [9, 10]. 
Calibration curve of tramadol in 0.1 N HCL 
From this stock solution dilutions were made in 0.1 N HCL in order 
to get 2μg/ml, 4 μg/ml, 6 μg/ml, 8μg/ml, 10μg/ml, the absorbance of 
these solutions were measured at λ max
Standard Stock solution: 100 mg of tramadol was dissolved in a sufficient 
amount of ethanol and makeup to 100 ml of pH6.8 phosphate buffer to 
give a concentration of 1000 μg/ml (stock solution A). From the stock 
solution (stock A) pippet out 1 ml and was make up to 10 ml to give a 
concentration 100μg/ml (stock solution B), from this stock solution 
subsequent dilutions were made in phosphate buffer pH 6.8 in order to 
get 2μg/ml, 4μg/ml, 6μg/ml, 8μg/ml, 10μg/ml, absorbance of these 
solutions were measured at λmax 270 nm using uv-visible 
spectrophotometer and standard curve was plotted. The linearity plot 
was obtained for the aliquot concentration of 2, 4, 6, 8; 10μg/ml with the 
absorbance was seen at 270 nm [11-14]. 
 270 nm using UV-visible 
spectrophotometer and the standard curve was plotted. The 
linearity plot was obtained for the aliquot concentration of 2, 4, 6, 8; 
10μg/ml with the absorbance was seen at 270 nm.  
Calibration curve of tramadol in pH 6.8 phosphate buffer 
Drug-excipient compatibility study 
Infrared spectroscopy is a useful analytical technique utilized to 
check the chemical interaction between the drug and excipients 
used in the formulation.1-2 mg of solid fine powder of drug tramadol 
and 200-300 mg of dry powder of KBr (IR grade) were taken in a 
mortar and mixed well with the help of a spatula. Spectrum 
measurement was carried out using KBr disk method in the 
wavelength region of 4000-400 cm-1 by FTIR spectrophotometer 
[15-16]. The IR spectrum of the physical mixture was compared 
with that of the pure drug to check any possible drug-excipient 
interaction. The spectrum of FT-IR is shown in fig. 4 and 5. 
Formulation of an extended-release tablet 
In the formulations prepared, the release retardants included were 
hydroxyl propyl methyl cellulose (HPMC K15M, HPMC K100M CR), 
polyethylene oxide (PEO) and microcrystalline cellulose (MCC), 
magnesium stearate (MS) 1% and talc 2 % were used as lubricants. 5% 
w/v solution of polyvinyl pyrrolidone (PVP-K30) in isopropyl alcohol 
(IPA) was used as a binder. Compositions of different formulations were 
given in the following tables no 1-3. Microcrystalline cellulose, PVP K30 
were weighed according to the given table and sifted through 40 mesh. 
To the above blend tramadol was added and sifted through 18 mesh. The 
sifted materials were mixed for 10 min. Magnesium stearate and talc 
were weighed and sifted through 40 mesh. To the powdered blend, the 
lubricated blend was added and mixed properly. Then the total blend 
was used for Pre-compression parameters and then compressed using 8 
mm round punches [17-20].  
Pre-compression parameters 
The following pre-compression parameter was evaluated like bulk 
density and tapped density, angle of repose, Hausner's ratio and 
compressibility index (%). 
 
Table 1: Composition of matrix tablets containing HPMC K15M 
Ingredients (mg)  Formulation code 
T1 T2 T3 T4 
Tramadol 100 100 100 100 
HPMC K15M 12.25 25 50 100 
MCC Qs qs qs qs 
PVP-K90 6 6 6 6 
IPA Qs qs qs qs 
Mg stearate 1.2 1.2 1.2 1.2 
Talc 2.4 2.4 2.4 2.4 
Total weight 400 400 400 400 
*qs = quantity sufficient  
 
Table: 2 Composition of matrix tablets containing polyethylene oxide 
Ingredients (mg)  Formulation code 
T5 T6 T7 T8 
Tramadol 100 100 100 100 
Polyethylene oxide 12.25 25 50 100 
MCC Qs qs qs qs 
PVP-K90 6 6 6 6 
IPA Qs qs qs qs 
Mg stearate 1.2 1.2 1.2 1.2 
Talc 2.4 2.4 2.4 2.4 
Total weight 400 400 400 400 
*qs = quantity sufficient  
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Table 3: Composition of matrix tablets containing HPMC K100M 
Ingredients (mg)  Formulation code 
T9 T10 T11 T12 
Tramadol 100 100 100 100 
HPMC K100M 12.25 25 50 100 
MCC Qs qs qs qs 
PVP-K90 6 6 6 6 
IPA Qs qs qs qs 
Mg stearate 1.2 1.2 1.2 1.2 
Talc 2.4 2.4 2.4 2.4 
Total weight 400 400 400 400 
*qs = quantity sufficient  
 
Bulk density and tapped density 
Both loose bulk density (LBD) and tapped bulk density (TBD) were 
determined. First 25 gm of the blend from each formulation was 
weight accurately and kept into a cleaned dried 50 ml graduated 
measuring cylinder. After than initial volume was noted is called as 
bulk volume and the bulk density is calculated by the following 
formula [21-22]. The results are given in the table 13. 
Bulk density = Weight of blend (gram)/Bulk volume of the blend 
After measuring bulk volume the same measuring cylinder subject 
to 500 tap with the help of bulk density measuring Apparatus. The 
tapped volume occupied by the powder is recorded. Then the tapped 
density is measured by the following formula. The outcomes are 
given in the table 13. 
Tapped density =  
Angle of repose 
The angle of repose of powdered blend was determined by the 
funnel method. The accurately weight 15 gm powdered blend was 
taken in the funnel. The height of the funnel was adjusted in such a 
way that the tip of the funnel just touched the apex of the blend. The 
powdered blend was allowed to flow through the funnel freely on to 
the surface. The diameter of the powder cone was measured and the 
angle of repose was calculated using the following equation [23, 24]. 




θ=Angle of repose 
h = Height of the powder cone 
r = Average radius of the powder cone 
 
Table 4: Relationship between the angle of repose and powder flow 
S. No. Angle of repose Flow property 
1 <25 Excellent 
2 25-30 Good 
3 30-40 Passable 
4 40 and above Very poor 
 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of powder flow which is 
calculated by the following formula. The outcomes are given in the 
table 12 
Hausner’s Ratio =  
Compressibility index (%) 
It is also one of the simple methods to evaluate flow property of powder 
by comparing the bulk density and tapped density is calculated by the 
following formula [25-27]. The outcomes are given in the table 12 
 
Table 5: Relationship between Hausner's ratio and powder flow 






Very Poor 1.46–1.59 
Very, Very Poor >1.60 
 
Table 6: Relationship belongings compressibility index and powder flow 
S. No. Compressibility Index (%) Flow property  
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Passable 
4 23-35 Poor 
5 33-38 Very poor 
6 <40 Very very poor 
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Evaluations of the tablet 
Thickness 
The thickness of the tablets is measured by vernier calipers and it is 
expressed in mm. Tablet thickness should be controlled within a±5% 
variation of standard value the outcomes are given in table 13. 
Hardness 
Tablets require strength or hardness to withstand mechanical 
shocks of handling in the manufacture, packing and shipping. 
Tablet hardness was measured by monsanto hardness tester and 
results are expressed in Kg/cm2
Weight variation test 
. The outcome are given in the 
table 13 
20 tablets were weighed individually. Average weight was calculated 
from the total weight of all tablets. The individual weights were 
compared with the average weight. The percentage difference in the 
weight variation should be within the permissible limits (±5%). The 
percent deviation was calculated using the following formula. The 
acceptance limits are as per United States pharmacopeia (USP) [28]. 
The outcome are given in the table 13 
 
Table 7: Limits for tablet weight variation test (USP) 
Average weight of tablet  (mg) % Difference allowed 
130 or less 10 % 
From 130 to 324 7.5 % 
>324 5 % 
 
Friability  
It was performed in roche friabilator where the tablets were 
subjected to the combined effect of abrasion and shock by utilizing a 
plastic chamber that revolves at 25 rpm dropping the tablets at a 
distance of six inches with each revolution in the chamber. Pre-
weighted samples of 20 tablets were placed in the friabilator, which 
is then operated for 100 revolutions. The tablets are then dusted and 
reweighed. Permitted friability limit is 1.0%. The percent friability 
was determined using the following formula [29-30]. 
% Friability=  X100 
Drug content uniformity 
The content uniformity test is used to ensure that every tablet 
contains the amount of drug substance intended with little variation 
among tablets within a batch. Randomly 30 tablets were selected 
from which 10 tablets were taken and triturated well in a mortar. 
The quantity equivalent to 100 mg of tramadol was dissolved in 100 
ml of phosphate buffer pH 6.8 solutions on a rotary shaker 
overnight. The absorbance was measured using UV-Visible 
spectrophotometer at 270 nm [31-32]. The outcomes are given in 
the table 13. 
In vitro dissolution studies 
The dissolution rate of extended-release tablets from all 
formulations was performed using LAB INDIA dissolution apparatus 
(USP II) with paddle. The dissolution fluid was 900 ml 0.1N HCL for 
first 2 h then replaced with phosphate buffer pH 6.8 at a speed of 50 
rpm and a temperature of 37±0.5 °C were used in each test. The 
dissolution experiments were conducted in triplicate. For all tests 5 
ml samples of the test medium were collected at set intervals (1, 2, 4, 
6, 8, 12, 18and 24 h) and were replaced with equal volume of 
phosphate buffer pH 6.8. The samples were analyzed at 270 nm 
using a UV spectrophotometer [33-35]. 
Kinetic analysis of dissolution data  
In order to determine the release mechanism that provides the best 
description to the pattern of drug release, the in vitro release data 
were fitted to zero-order, first-order, hixson crowell, and 
Korsemeyer-Peppas model [36-37]. The data of the regression 
coefficient of different kinetic models were summarized in table 17. 
RESULTS 
Preformulation study: These test results were illustrated below 
  
Table 8: table showing the description of tramadol (API) 
Test  Description 
Colour White or almost white crystalline powder 
Odour Free of odour 
Solubility: These tests results were illustrated below 
 
Table 9: Solubility of tramadol (API) in various solvents 
Solvents Solubility 
Water  Freely soluble  
Methanol Freely soluble 
Acetone Slightly soluble 
 
Preparation of standard calibration curve of tramadol 
Standard graph of tramadol in 0.1 N HCl 
In the pre-formulation study, it was found that the λmax of 
tramadol by the spectrophotometric method in phosphate buffer 
0.1N HCL was found to be 270 nm. The spectrum was shown in 
fig. 
Drug and excipients compatibility studies 
FTIR studies conducted on pure drug tramadol and the optimize 
formulation (T6) given in fig. 4 and 5, which showed that there is 
no marked interaction between drug and excipients used. 
Characterization of tramadol powder blend  
The blends for tramadol tablets were characterized with respect to the 
angle of repose, bulk density, tapped density, carr’s index, and 
hausner’s ratio. Angle of repose was between 22.7 ° to 28.5 ° and carr’s 
index values were less than 15 for the blend of all the batches 
indicating excellent to good flowability and compressibility. Hausner’s 
ratio was less than 1.25 for all the batches indicating excellent flow 
properties. The results were summarized in table 12. 
Evaluation of physical parameter 
The physical properties of tramadol extended-release tablets were 
given in table 13. Tablet thickness should be controlled within a±5% 
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variation of standard value. The prepared tablets in all the 
formulations possessed good mechanical strength with sufficient 
hardness in the range of 6.0±0.21 to 6.7±0.41 kg/cm2
 
. Friability 
values below 1% (0.32±0.62-0.42±0.42%) were an indication of 
good mechanical resistance of the tablets. All the tablets from each 
formulation passed weight variation test, as the % weight variation 
was within the pharmacopoeial limits of±5% of the weight. The 
weight variation in all the formulations was found to be 398±1.56 to 
409±1.23 mg, which was in pharmacopoeial limits of±5% of the 
average weight. The percentage drug content of all the tablets was 
found to be between 98.2±0.66% to 103±0.68% of Tramadol which 
was within the acceptable limits. 
 
Fig. 1: λmax of tramadol 
 
Table 10: Concentration and absorbance of tramadol in 0.1 N HCl 










Fig. 2: Calibration curve of tramadol in 0.1N HCL 
 
Table 11: Concentration and absorbance of tramadol in pH 6.8 phosphate buffer 
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Fig. 3: Calibration curve of tramadol in pH 6.8 phosphate buffer 
 
 
Fig. 4: FTIR spectra of tramadol pure drug 
 
 
Fig. 5: FTIR Spectra of tramadol optimized formulation 
 
Table 12: Preformulation parameters of tramadol matrix tablets 












1 T1 0.43±0.022 0.49±0.060 12.24±1.38 22.7 °±0.21 1.13±0.021 
2 T2 0.41±0.029 0.47±0.021 12.76±2.52 25.7 °±0.45 1.14±0.024 
3 T3 0.46±0.019 0.53±0.035 13.20±1.15 26.1 °±0.32 1.15±0.023 
4 T4 0.44±0.021 0.51±0.024 13.72±2.63 25.9 °±0.44 1.15±0.015 
5 T5 0.40±0.036 0.47±0.028 14.89±1.69 24.3 °±0.26 1.17±0.021 
6 T6 0.37±0.012 0.43±0.011 13.95±0.98 26.6 °±0.16 1.16±0.011 
7 T7 0.41±0.052 0.48±0.021 14.58±1.35 25.5 °±0.50 1.17±0.021 
8 T8 0.34±0.045 0.39±0.028 12.82±1.45 24.9 °±1.39 1.14±0.021 
9 T9 0.38±0.032 0.44±0.041 13.63±2.48 26.6 °±0.35 1.15±0.023 
10 T10 0.33±0.028 0.38±0.015 13.15±2.36 28.5 °±0.47 1.15±0.021 
11 T11 0.40±0.024 0.47±0.018 14.89±1.77 24.3 °±0.78 1.17±0.024 
12 T12 0.37±0.063 0.43±0.025 13.95±1.65 26.6 °±0.66 1.16±0.029 
*Average of three observations (n=3), *All the values are expressed as mean±SD 
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Table 13: Post formulation parameters of tramadol matrix tablets 
Formulation code Hardness (Kg/cm2) Weight variation (mg)* Thickness (mm)* Friability (%)* Drug content (%)* * 
T1 6.0±0.21 401±1.13 2.22±0.033 0.35±0.55 99.7±0.85 
T2 6.6±0.32 409±1.23 2.12±0.086 0.32±0.62 103.7±0.44 
T3 6.1±0.41 400±1.22 2.20±0.019 0.34±0.28 99.4±0.64 
T4 6.2±0.23 398±1.56 2.19±0.086 0.37±0.26 101±0.86 
T5 6.4±0.22 401±1.24 2.15±0.037 0.33±0.65 98.6±2.19 
T6 6.3±0.22 400±0.98 2.17±0.011 0.42±0.42 103±0.68 
T7 6.5±0.42 399±1.44 2.14±0.067 0.39±0.25 99.5±0.52 
T8 6.7±0.41 401±0.99 2.11±0.069 0.34±0.86 98.2±0.66 
T9 6.4±0.21 400±1.55 2.16±0.073 0.42±0.22 101±0.49 
T10 6.5±0.26 399±1.36 2.13±0.031 0.38±0.55 99.3±0.91 
T11 6.5±0.28 399±1.91 2.14±0.088 0.39±0.59 99.5±0.72 
T12 6.2±0.39 398±1.83 2.19±0.061 0.37±0.34 102.5±0.62 
*Average of three observations (n=3), *All the values are expressed as mean±SD 
 
In vitro dissolution study 
In vitro drug release studies in 0.1 N HCl (First 2 h) and 6.8 pH 
phosphate buffer show drug release from range 92.3±0.23% 
to100.2±1.36% all formulation. The plots of % aggregate Tramadol 
release versus time (min) were plotted and delineated as 
appeared in fig. 7. The formulation T6 indicated a higher release 
rate of 100.2% In 24 H. uncovering that formulation made with 
convergences of PEO 50 mg, T6 was picked as the improved 
formulation. 
 
Table 14: Dissolution data of formulation HPMC K15M (T1-T4) 
Time (h) T1(% of drug release)* T2 (% of drug release)* T3 (% of drug release)* T4 (% of drug release)* 
1 36.1±0.24 17.5±0.95 21±0.33 35.7±0.33 
2 42.4±0.55 21.8±0.22 29.4±0.73 44.0±0.45 
3 63.7±0.33 25.6±0.73 48.9±0.92 56.1±0.49 
4 78.9±0.99 59.4±0.71 54.8±0.37 68.8±0.50 
6 86.3±0.25 78.4±0.49 74.5±0.97 76.3±0.54 
8 92.3±0.23 89.6±0.97 86.8±0.92 82.5±0.69 
12 -- 99.2±1.72 95.4±1.22 89.5±0.88 
16 -- -- 99.8±1.47 95.6±1.2 
20 -- -- -- 99.6±1.25 
24 -- -- -- -- 
*Average of three observations (n=3), *All the values are expressed as mean±SD 
 
Table 15: Dissolution data of formulation containing polyethylene oxide (T5-T8) 
Time(h) T5(% of drug release) T6(% of drug release)* T7 (% of drug release)* T8(% of drug release)* * 
1 19.8±0.27 20.6±0.22 14.3±0.28 18.4±0.29 
2 27.3±0.38 29.3±0.33 26.4±0.37 34.8±0.37 
3 38.4±0.49 36.8±0.48 58.5±0.42 56.1±0.47 
4 45.9±0.44 44.2±0.49 98.6±0.48 72.2±0.59 
6 56.4±0.56 59.1±0.56 -- 97.8±0.78 
8 68.1±0.59 64.1±0.59 -- -- 
12 77.3±0.88 76.5±0.66 -- -- 
16 89.4±1.99 92.4±0.69 -- -- 
20 99.8±1.25 97.1±1.29 -- -- 
24 -- 100.2±1.36 -- -- 
*Average of three observations (n=3), *All the values are expressed as mean±SD 
 
Table 16: Dissolution data of formulation containing HPMC K100M (T9-T12) 
Time (h) T9(% of drug release) T10 (% of drug release) * T11(% of drug release) T12(% of drug release)* * 
1 38.7±0.28 25.0±0.75 28.2±0.92 20.0±0.31 
2 41.0±0.37 34.1±0.95 35.6±0.48 30.4±0.73 
3 79.5±0.48 46.9±0.96 48.2±0.99 49.9±0.92 
4 99.2±0.88 57.2±0.47 55.6±1.25  56.8±0.52 
6 -- 63.3±0.88 62.4±1.76 68.3±0.94 
8 -- 70±0.82 79.3±1.8 82.5±1.21 
12 -- 99.4±0.89 86.2±1.9 90.2±0.97 
16 -- -- 99.5±1.9 95.5±0.73 
20 -- -- -- 99.8±0.46 
24 -- -- -- -- 
*Average of three observations (n=3), *All the values are expressed as mean±SD 
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Fig. 6: Dissolution profile of formulations T1-T4 
 
 
Fig. 7: Dissolution profile of formulations T5–T8 
 
 
Fig. 8: Dissolution profile of formulations T9–T12 
 
Kinetic studies for optimized formulation 
For analyzing the release mechanism, the data obtained were fitted to 
various kinetic equations of Zero order, First order, Higuchi model and 
Korsmeyer-Peppas model. The regression coefficient was calculated. It 
was concluded that the optimized formulations T6 follows zero order 
kinetics as correlation coefficient (r2
 
) values are higher than that of 
first-order release kinetics. In order to understand the complex 
mechanism of drug release from the matrix system, the in vitro release 
rate were fitted to korsmeyer-peppas model and interpretation of 
release exponent value (n) enlighten in understanding the release 
mechanism from the dosage form. The release exponent value (n) 
obtained was 0.82105. The T6 formulation exhibited anomalous (non-
fickian) diffusion mechanism. Kinetic studies shows that the amount of 
drug from the matrix system was by both diffusion and erosion. There 
is a good scope for the development of extended-release tablets for 
this drug. The data of the regression coefficient of different kinetic 
models were summarized in table 17. 
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Table 17: Release kinetics for the optimized formulation T6 
 Zero First Higuchi Peppas 
 % CDR Vs T Log % drug Remain Vs Time %CDR Vs √T Log% of CDR Vs Log T 
Slope 4.227962963 -0.063258255 21.3693521 0.821051124 
Intercept 0.833641975 2.166610516 -16.87673946 0.419307821 
Correlation 0.996837882 -0.923901295 0.963694821 0.956451967 
R 0.993685763 2 0.853593602 0.928707708 0.914800364 
 
 
Fig. 9: Zero order plots for optimized formulation T6 
 
 
Fig. 10: First order plot for optimized formulation T6 
 
 
Fig. 11: Higuchi plot for optimized formulation T6 
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Fig. 12: Peppas plot for optimized formulation T6 
 
CONCLUSION 
An extended release tablet of tramadol was prepared by wet 
granulation using polymer like hydroxypropyl methylcellulose K100M, 
K15M and polyethylene oxide (PEO). Based on the stated results of 
formulation coded T6 shows more sustained action and optimum 
release than remaining all, which indicates that the concentration of 
polymer polyethylene oxide was found to play a vital role in 
controlling the release of tramadol from the matrix system. 
Accordingly, it can be concluded that the formulation is robust in the 
performance is less likely to be affected by the various factors studied. 
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